The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery

被引:2
|
作者
Castaneda, Javier [1 ]
de Galan, Bastiaan E. [2 ,3 ,4 ]
van Kuijk, Sander M. J. [5 ]
Arrieta, Arcelia [1 ]
van den Heuvel, Tim [1 ]
Cohen, Ohad [1 ]
机构
[1] Medtron Int Trading Sarl, Route Molliau 31, CH-1131 Tolochenaz, Switzerland
[2] Maastricht Univ Med Ctr, Dept Internal Med, Maastricht, Netherlands
[3] Maastricht Univ, CARIM Sch Cardiovasc Dis, Maastricht, Netherlands
[4] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands
[5] Maastricht Univ Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
来源
DIABETES OBESITY & METABOLISM | 2024年 / 26卷 / 12期
关键词
glycaemic control; hypoglycaemia; mean glucose; real-world evidence; time in tight glucose range; REAL-WORLD USERS; SYSTEM; RANGE; TIME;
D O I
10.1111/dom.15955
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: The aim was to determine the interdependence of targets for glucose management indicator (GMI), time within the ranges of 70-180 mg/dL (TIR) and 70-140 mg/ dL (time in tight glucose range [TITR]), time above 180 mg/dL (TA180) and 250 mg/ dL (TA250) and time below 70 mg/dL (TB70) and 54 mg/dL (TB54) and its implications for setting targets in automated insulin delivery (AID). Materials and Methods: Real-world data from individuals with type 1 diabetes using the 780G system were used to calculate the receiver operating characteristic curves and establish interdependent targets for time in ranges based on several GMI benchmarks. Correlation, regression and principal component analysis were used to determine their association and dimensionality. Results: In individuals aged >15 years (n n = 41 692), a GMI <6.5% required targets of >81%, >58%, <15% and <1.9% for TIR, TITR, TA180 and TA250, respectively, with high sensitivity, specificity and accuracy (>90%), whereas these values were poor for time in hypoglycaemia and GMI, which had a modest correlation (-0.21 to-0.43). Two dimensions emerged: (1) GMI, TIR, TITR, TA180 and TA250, and (2) TB70 and TB54, explaining 95% of total variability. GMI (or TIR) and TB70 explained >81% of the variability in the remaining continuous glucose monitoring (CGM) metrics, providing accurate predictions. Individuals aged <= 15 years (n n = 14 459) showed similar results. Conclusion: We developed a methodology to establish interdependent CGM targets for therapies with CGM data outputs. In AID with the 780G system, a GMI <7% requires time in ranges close to consensus targets. Targets for GMI, TIR, TITR, TA180 and TA250 could be reduced to targets for GMI or TIR, whereas targets for time in hypoglycaemia are not inherently tied to GMI/TIR targets.
引用
收藏
页码:5836 / 5844
页数:9
相关论文
共 50 条
  • [21] Insulin Pumps and Continuous Glucose Monitoring in Pediatric Patients With Type 1 Diabetes Mellitus
    Tamborlane, William V.
    ENDOCRINE PRACTICE, 2012, 18 : 13 - 16
  • [22] Associations of insulin pump and continuous glucose monitoring use with pregnancy-related outcomes in women with type 1 diabetes
    Wang, Zifan
    James-Todd, Tamarra M.
    Isganaitis, Elvira
    O'Connell, Julianne
    Helman, Sarit
    Wyckoff, Jennifer A.
    Serdy, Shanti
    Halprin, Elizabeth
    O'Brien, Karen
    Gupta, Munish
    Brown, Florence M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 187
  • [23] Cutaneous Reactions to Continuous Glucose Monitoring and Continuous Subcutaneous Insulin Infusion Devices in Type 1 Diabetes
    Severin, Rachel K.
    Gandica, Rachelle
    Levin, Laura E.
    Belsito, Donald V.
    Garzon, Maria C.
    Williams, Kristen M.
    DIABETES, 2018, 67
  • [24] Effect of Automated Insulin Delivery on Glucose Counterregulation in Long-Standing Type 1 Diabetes
    Flatt, Anneliese
    Peleckis, Amy J.
    Dalton-Bakes, Cornelia V.
    Nguyen, Huong-Lan T.
    Ilany, Sarah
    Matus, Austin M.
    Malone, Susan K.
    Jang, Sooyong
    Weimer, James
    Lee, Insup
    Rickels, Michael R.
    DIABETES, 2022, 71
  • [25] Continuous Glucose Monitoring in Youth with Type 1 Diabetes
    Wadwa, R. Paul
    Fiallo-Scharer, Rosanna
    VanderWel, Brandon
    Messer, Laurel H.
    Cobry, Erin
    Chase, H. Peter
    DIABETES TECHNOLOGY & THERAPEUTICS, 2009, 11 : S83 - S91
  • [26] Continuous Glucose Monitoring and Type 1 Diabetes Reply
    Tamborlane, William V.
    Beck, Roy W.
    Laffel, Lori
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02): : 191 - 192
  • [27] Continuous glucose monitoring in type 1 diabetes mellitus
    Pavlicek, Vojtech
    DIABETOLOGE, 2019, 15 (08): : 744 - 746
  • [28] Continuous glucose monitoring in type 1 diabetes mellitus
    Tamborlane, William V.
    Beck, Roy W.
    LANCET, 2009, 373 (9677): : 1744 - 1746
  • [29] Continuous glucose monitoring in children with type 1 diabetes
    不详
    JOURNAL OF PEDIATRICS, 2007, 151 (04): : 388 - 393
  • [30] Continuous glucose monitoring in persons with type 2 diabetes not using insulin
    Cowart, Kevin
    Updike, Wendy H.
    Franks, Rachel
    EXPERT REVIEW OF MEDICAL DEVICES, 2021, 18 (11) : 1049 - 1055